Drug major Lupin has received approval of the US Food and Drug Administration (FDA) to market a generic version of ViiV Healthcare’s ‘Epivir’ tablets, used in treating HIV infection, in the American market. Shares in Lupin rose nearly 1 per cent during the day.
The Mumbai-based firm has received final approval from the US drug regulator for ‘Lamivudine’ tablets in strengths of 150 mg and 300 mg, Lupin Ltd said in a statement.
Lupin Pharmaceuticals Inc (LPI), the company’s US subsidiary, would commence marketing the product shortly, it added.
Epivir tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection.
According to IMS MAT September 2014 sales data, Epivir tablets had annual US sales of $39.7 million.
Shares in Lupin, on Friday, ended at Rs 1406.40 apiece on the BSE, up 0.26 per cent from the previous close.